Oncology Data Advisor™ · Studying Olutasidenib in Relapsed/Refractory Acute Myeloid Leukemia With Jorge Cortes, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Jorge Cortes, Director of the Georgia Cancer Center in Augusta, Georgia, sat down with Oncology Data Advisor to discuss his presentation regarding the results of a pivotal phase 2 study in which olutasidenib was studied in patients with relapsed/refractory isocitrate dehydrogenase 1 (IDH1)...

The FDA has granted approval to olutasidenib (Rezlidhia™, Rigel Pharmaceuticals Inc.) for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase 1 gene (IDH1) mutation. Additionally, the FDA granted approval to the Abbott RealTime IDH1 Assay to accurately detect and select patients to receive olutasidenib. Olutasidenib is an inhibitor specific to mutant IDH1. "Mutation of IDH1 occurs in 7% to 14% of patients with AML," wro...